ARIAD Announces Webcast of Its Annual Stockholders Meeting.CAMBRIDGE, Mass. -- ARIAD ARIAD Allison Research Index of Art and Design Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ARIA) today announced that its Annual Meeting of Stockholders on June 12, 2008 will be webcast live and can be accessed by visiting the investor relations Investor relations The process by which the corporation communicates with its investors. section of the Company's website at http://www.ariad.com. The annual meeting will take place at 10:00 a.m. (ET) at the Company's headquarters in Cambridge, Massachusetts This article is about the city of Cambridge in Massachusetts. For the English university town, see Cambridge, England. For other places, see Cambridge (disambiguation). Cambridge, Massachusetts is a city in the Greater Boston area of Massachusetts, United States. and will include an overview of the Company and its key programs provided by Harvey J. Berger, M.D., chairman and chief executive officer at ARIAD. A replay will be available on the ARIAD website approximately three hours after the presentation and will be archived for two weeks. To ensure a timely connection to the live webcast, participants should log on to the webcast at least fifteen minutes prior to the scheduled start time. About ARIAD ARIAD is engaged in the discovery and development of breakthrough medicines to treat cancer by regulating cell signaling Cell signaling is part of a complex system of communication that governs basic cellular activities and coordinates cell actions. The ability of cells to perceive and correctly respond to their microenvironment is the basis of development, tissue repair, and immunity as well as with small molecules. ARIAD is developing a comprehensive approach to patients with cancer that addresses the greatest medical need - aggressive and advanced-stage cancers for which current treatments are inadequate. ARIAD has a global partnership with Merck & Co., Inc. to develop and commercialize deforolimus, ARIAD's lead cancer product candidate, which is in Phase 3 clinical development. ARIAD's second oncology product candidate, oral AP24534, is a novel multi-targeted kinase inhibitor in Phase 1 clinical development in hematological hematological, hematologic pertaining to or emanating from blood cells. hematological tests total and differential white cell counts, hematocrit estimation, erythrocyte count. cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-kB treatment methods, and the discovery and development of drugs to regulate NF-kB cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at http://www.ariad.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion